1. Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Differential Diagnosis of Monoclonal Gammopathies Mayo Clinic, Rochester, MN

4. Types of Amyloidosis Mayo Clinic, Rochester, MN, 2016

5. Light-Chain Amyloidosis

6. Biology of Amyloidosis

7. Nonspecific Symptoms

8. AL Amyloidosis Patient Experience Survey From ARC

9. AL Amyloidosis Patient Experience Survey From ARC (cont)

10. Organ Involvement in Patients With AL Amyloidosis

11. Key Signs of AL Amyloidosis

12. Case 1: 78-Year-Old Woman

13. Case 1: Biopsy Specimens From 78-Year-Old Woman

14. Case 2: 79-Year-Old Man

15. Case 3: Patient With Suspected Atypical MM

16. Case 3: BM Biopsy Congo Red X1000

17. Diagnostic Algorithm for Amyloidosis

18. Diagnostic Algorithm for Amyloidosis (cont)

19. Treatment Algorithm for AL Amyloidosis

20. Activity of Pomalidomide in Patients With AL

21. Potential Amyloid Active Agents

22. CPHPC Plus Anti-SAP mAb for Systemic Amyloidosis

23. First Compound for Diagnosis and Treatment of AL Amyloidosis: 11-1F4 mAb

24. NEOD001 Phase 1/2 Study: Expansion and Dose-Escalation

25. NEOD001 Phase 1/2 Study: Conclusions

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)